Skip to main content
SpringerLink
Log in

Use of atypical antipsychotics for treatment-resistant major depressive disorder

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Despite the progressive increase in the number of pharmacologic agents with potential antidepressant activity, many patients suffering from major depressive disorder (MDD) continue to be symptomatic. Clearly, an urgent need exists to develop safer, better tolerated, and more effective treatments for MDD. Use of atypical antipsychotic agents as adjunctive treatment for treatment-resistant MDD (TRD) represents one such effort toward novel pharmacotherapy development. Atypical antipsychotic agents have been hypothesized to be beneficial in treating mood disorders, including TRD, as a result of their complex mechanisms of action. After an initial series of positive case reports, series, and small clinical trials, subsequent larger-scale projects have yielded conflicting results. However, more recently, larger-scale clinical trials have supported the effectiveness of at least some of these medications. This review summarizes the existing data regarding the effectiveness of these medications in treating TRD, including biochemical rationale and clinical data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28–40.

    Article  PubMed  Google Scholar 

  2. Petersen T, Papakostas GI, Posternak MA, et al.: Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005, 25:336–341.

    Article  PubMed  Google Scholar 

  3. Papakostas GI, Petersen T, Denninger JW, et al.: Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004, 24:507–511.

    Article  PubMed  CAS  Google Scholar 

  4. Paykel ES, Ramana R, Cooper Z, et al.: Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995, 25:1171–1180.

    Article  PubMed  CAS  Google Scholar 

  5. Thase ME, Friedman ES, Biggs MM, et al.: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007, 164:739–752.

    Article  PubMed  Google Scholar 

  6. UK ECT Review Group: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003, 361:799–808.

    Article  Google Scholar 

  7. Rush AJ, Marangell LB, Sackeim HA, et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58:347–354.

    Article  PubMed  Google Scholar 

  8. O’Reardon JP, Solvason HB, Janicak PG, et al.: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007, 62:1208–1216.

    Article  PubMed  Google Scholar 

  9. Fava M, Alpert J, Nierenberg A, et al.: Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002, 22:379–387.

    Article  PubMed  CAS  Google Scholar 

  10. Papakostas GI, Fava M, Thase ME: Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008, 63:699–704.

    Article  PubMed  CAS  Google Scholar 

  11. Rush AJ, Trivedi MH, Wisniewski SR, et al.: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006, 354:1231–1242.

    Article  PubMed  CAS  Google Scholar 

  12. Fava M, Rush AJ, Wisniewski SR, et al.: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006, 163:1161–1172.

    Article  PubMed  Google Scholar 

  13. McGrath PJ, Stewart JW, Fava M, et al.: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006, 163:1531–1541.

    Article  PubMed  Google Scholar 

  14. Trivedi MH, Fava M, Wisniewski SR, et al.: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354:1243–1252.

    Article  PubMed  CAS  Google Scholar 

  15. Carpenter LL, Yasmin S, Price LH: A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002, 51:183–188.

    Article  PubMed  CAS  Google Scholar 

  16. Nelson JC, Mazure CM, Jatlow PI, et al.: Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004, 55:296–300.

    Article  PubMed  CAS  Google Scholar 

  17. Nierenberg AA, Papakostas GI, Petersen T, et al.: Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003, 23:92–95.

    Article  PubMed  CAS  Google Scholar 

  18. Nierenberg AA, Fava M, Trivedi MH, et al.: A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006, 163:1519–1530.

    Article  PubMed  Google Scholar 

  19. Ballesteros J, Callado LF: Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004, 79:137–147.

    Article  PubMed  CAS  Google Scholar 

  20. Peet M, Horrobin DF: A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002, 59:913–919.

    Article  PubMed  CAS  Google Scholar 

  21. Patkar AA, Masand PS, Pae CU, et al.: A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006, 26:653–656.

    Article  PubMed  CAS  Google Scholar 

  22. Ravindran AV, Kennedy SH, O’Donovan MC, et al.: Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebocontrolled trial. J Clin Psychiatry 2008, 69:87–94.

    PubMed  CAS  Google Scholar 

  23. Alpert JE, Mischoulon D, Rubenstein GE, et al.: Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002, 14:33–38.

    PubMed  Google Scholar 

  24. Alpert JE, Papakostas G, Mischoulon D, et al.: S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004, 24:661–664.

    Article  PubMed  CAS  Google Scholar 

  25. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29–39.

    Article  PubMed  CAS  Google Scholar 

  26. Shapiro DA, Renock S, Arrington E, et al.: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400–1411.

    Article  PubMed  CAS  Google Scholar 

  27. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003, 64(Suppl 19):6–12.

    Google Scholar 

  28. Feiger AD, Heiser JF, Shrivastava RK, et al.: Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003, 64:243–249.

    PubMed  CAS  Google Scholar 

  29. Cunningham LA, Borison RL, Carman JS, et al.: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994, 14:99–106.

    Article  PubMed  CAS  Google Scholar 

  30. Feighner J, Targum SD, Bennett ME, et al.: A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 1998, 59:246–253.

    PubMed  CAS  Google Scholar 

  31. Kikuchi T, Tottori K, Uwahodo Y, et al.: 7-(4-[4-[2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14957), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995, 274:329–336.

    PubMed  CAS  Google Scholar 

  32. Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996, 277:137–143.

    PubMed  CAS  Google Scholar 

  33. Matsubayashi H, Amano T, Sasa M: Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl) 1999, 146:139–143.

    Article  CAS  Google Scholar 

  34. Lawler CP, Prioleau C, Lewis MM, et al.: Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612–627.

    Article  PubMed  CAS  Google Scholar 

  35. Burris KD, Molski TF, Xu C, et al.: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002, 302:381–389.

    Article  PubMed  CAS  Google Scholar 

  36. Schmidt AW, Lebel A, Howard HR Jr, Zom SH: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001, 425:197–201.

    Article  PubMed  CAS  Google Scholar 

  37. Shelton RC, Tollefson GD, Tohen M, et al.: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158:131–134.

    Article  PubMed  CAS  Google Scholar 

  38. Shelton RC, Williamson DJ, Corya SA, et al.: Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005, 66:1289–1297.

    PubMed  CAS  Google Scholar 

  39. Corya SA, Williamson D, Sanger TM, et al.: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006, 23:364–372.

    Article  PubMed  CAS  Google Scholar 

  40. Thase ME, Corya SA, Osuntokun O, et al.: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatmentresistant major depressive disorder. J Clin Psychiatry 2007, 68:224–236.

    PubMed  CAS  Google Scholar 

  41. Tohen M, Vieta E, Calabrese J, et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60:1079–1088.

    Article  PubMed  CAS  Google Scholar 

  42. Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999, 60:256–259.

    PubMed  CAS  Google Scholar 

  43. Rapaport MH, Gharabawi GM, Canuso CM, et al.: Effects of risperidone augmentation in patients with treatmentresistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006, 31:2505–2513.

    Article  PubMed  CAS  Google Scholar 

  44. Mahmoud RA, Pandina GJ, Turkoz I, et al.: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007, 147:593–602.

    PubMed  Google Scholar 

  45. Keitner GI, Garlow SJ, Ryan CE: Risperidone augmentation for patients with difficult-to-treat major depression [poster]. Presented at the 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada; May 20–26, 2006.

  46. Mattingly G, Ilivicky H, Canale J, Anderson R: Quetiapine augmentation for treatment-resistant depression [poster]. Presented at the 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada; May 20–26, 2006.

  47. McIntyre A, Gendron A, McIntyre A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007, 24:487–494.

    Article  PubMed  CAS  Google Scholar 

  48. Khullar A, Chokka P, Fullerton D, et al.: Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: double blind, randomized, placebo controlled study [poster]. Presented at the 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada; May 20–26, 2006.

  49. Papakostas GI, Petersen TJ, Nierenberg AA, et al.: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65:217–221.

    Article  PubMed  CAS  Google Scholar 

  50. Dunner DL, Amsterdam JD, Shelton RC, et al.: Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007, 68:1071–1077.

    PubMed  CAS  Google Scholar 

  51. Papakostas GI, Petersen TJ, Kinrys G, et al.: Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005, 66:1326–1330.

    PubMed  CAS  Google Scholar 

  52. Berman RM, Marcus RN, Swanink R, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2007, 68:843–853.

    Article  PubMed  CAS  Google Scholar 

  53. Marcus RN, McQuade RD, Carson WH, et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:156–165.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC #812, Boston, MA, 02114, USA

    George I. Papakostas

Authors
  1. George I. Papakostas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard C. Shelton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George I. Papakostas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papakostas, G.I., Shelton, R.C. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep 10, 481–486 (2008). https://doi.org/10.1007/s11920-008-0077-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-008-0077-3

Keywords

Search

Navigation